Insulin-like growth factor 2 mRNA-binding protein 3 is a protein that in humans is encoded by the IGF2BP3gene.[1][2][3]
The protein encoded by this gene is primarily found in the nucleolus, where it can bind to the 5' UTR of the insulin-like growth factor II leader 3 mRNA and may repress translation of insulin-like growth factor II during late development. The encoded protein contains several KH domains, which are important in RNA binding and are known to be involved in RNA synthesis and metabolism. A pseudogene exists on chromosome 7, and there are putative pseudogenes on other chromosomes.[3]
↑Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Buchler M, Beger HG, Vila MR, Adler G, Gress TM (Jul 1997). "Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein". Oncogene. 14 (22): 2729–33. doi:10.1038/sj.onc.1201110. PMID9178771.
Yaniv K, Yisraeli JK (2002). "The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis". Gene. 287 (1–2): 49–54. doi:10.1016/S0378-1119(01)00866-6. PMID11992722.
Yisraeli JK (2005). "VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins". Biol. Cell. 97 (1): 87–96. doi:10.1042/BC20040151. PMID15601260.
Mueller-Pillasch F, Pohl B, Wilda M, et al. (2000). "Expression of the highly conserved RNA binding protein KOC in embryogenesis". Mech. Dev. 88 (1): 95–9. doi:10.1016/S0925-4773(99)00160-4. PMID10525192.
Zhang JY, Chan EK, Peng XX, et al. (2001). "Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies". Clin. Immunol. 100 (2): 149–56. doi:10.1006/clim.2001.5048. PMID11465943.
Yantiss RK, Woda BA, Fanger GR, et al. (2005). "KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas". Am. J. Surg. Pathol. 29 (2): 188–95. doi:10.1097/01.pas.0000149688.98333.54. PMID15644775.
Liao B, Hu Y, Herrick DJ, Brewer G (2005). "The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells". J. Biol. Chem. 280 (18): 18517–24. doi:10.1074/jbc.M500270200. PMID15753088.
Hammer NA, Hansen TO, Byskov AG, et al. (2005). "Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer". Reproduction. 130 (2): 203–12. doi:10.1530/rep.1.00664. PMID16049158.
Feagins LA, Susnow N, Zhang HY, et al. (2006). "Gain of allelic gene expression for IGF-II occurs frequently in Barrett's esophagus". Am. J. Physiol. Gastrointest. Liver Physiol. 290 (5): G871–5. doi:10.1152/ajpgi.00383.2005. PMID16339295.
Jiang Z, Chu PG, Woda BA, et al. (2006). "Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study". Lancet Oncol. 7 (7): 556–64. doi:10.1016/S1470-2045(06)70732-X. PMID16814207.
Li C, Rock KL, Woda BA, et al. (2007). "IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression". Mod. Pathol. 20 (2): 242–7. doi:10.1038/modpathol.3800735. PMID17192788.